在轻微的认知障碍中,牙周病和大脑粉样蛋白病理
J A Gil-Montoya1, M J Gerez-Muñoz2, E Triviño-Ibáñez3
1School of Dentistry, Universidad de Granada, Paseo de Cartuja s/n, 18071 Granada, Spain; Instituto de Investigación Biosanitaria de Granada, Avda. de Madrid, 15, 18012 Granada, Spain.
Neurologia
|September 3, 2025
概括
牙周病的特征是牙炎症,与大脑中β-粉样蛋白 (Aβ) 的较高水平有关,这是阿尔茨海默病 (AD) 的关键标志物. 这种关联在轻度认知障碍 (MCI) 患者中观察到.
科学领域:
- 神经科学
- 口腔健康问题
- 老年学
背景情况:
- 动物模型显示口腔病原体增加大脑β-粉样蛋白 (Aβ).
- 牙周炎是一种常见的口腔疾病,与全身炎症有关.
- 人类中牙周炎和脑Aβ积累之间的关系尚未完全理解.
研究的目的:
- 在轻度认知障碍 (MCI) 患者中研究牙周炎与大脑Aβ蛋白水平之间的关联.
- 确定牙周炎是否是大脑Aβ积累的风险因素,不论认知状态如何.
主要方法:
- 观察性研究,包括牙周检查和粉样蛋白PET扫描.
- 参与者分为三组:MCI/Aβ+ (n=45),MCI/Aβ- (n=59) 和认知健康的非MCI/Aβ- (n=60).
主要成果:
- 中度至重度牙周炎与异常脑Aβ积累的风险较高有关.
- 几率比 (OR) 为3. 30 (MCI/ Aβ+与MCI/ Aβ-) 和4. 94 (MCI/ Aβ+与非MCI/ Aβ-).
- 即使控制认知障碍时,这种联系仍然存在.
结论:
- 牙周病可能与老年人脑中的异常Aβ蛋白积累有关.
- 结果表明牙周炎可能是Aβ病理的独立风险因素.
- 需要进一步的研究来探索口腔健康与神经退行之间的机制联系.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


